Biohaven Ltd
BHVN
View Detailed Chart
13.890USD
-0.180-1.28%
Market hours （ET）Quotes delayed by 15 min
1.47BMarket Cap
LossP/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
-1.28%
5 Days
-13.57%
1 Month
+3.58%
6 Months
-52.77%
Year to Date
-62.81%
1 Year
-61.11%
View Detailed Chart
TradingKey Stock Score
Currency: USD Updated：2025-09-10Key Insights
Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Score
Support & Resistance
No Data
Score Analysis
Current score
Previous score
Analyst Rating
Based on
16
analysts
Buy
Current Rating
45.538
Target Price
+225.04%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Company Highlights
StrengthsRisks
Biohaven Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development, and commercialization of treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its clinical and preclinical programs include Kv7 ion channel modulation for epilepsy and mood disorders; extracellular protein degradation for immunological diseases; Transient Receptor Potential Melastatin 3 (TRPM3) antagonism for migraine and neuropathic pain; Tyrosine Kinase 2/Janus Kinase 1 (TYK2/JAK1) inhibition for neuroinflammatory disorders; glutamate modulation for obsessive-compulsive disorder (OCD) and spinocerebellar ataxia (SCA); myostatin inhibition for neuromuscular and metabolic diseases, including spinal muscular atrophy (SMA) and obesity; and antibody recruiting, bispecific molecules and antibody drug conjugates (ADCs) for cancer. The Troriluzole is a new chemical entity (NCE) and tripeptide prodrug of the active metabolite, riluzole.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 48.42.
Overvalued
The company’s latest PE is -1.88, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 102.09M shares, decreasing 10.12% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 9.23M shares of this stock.
News
More news coming soon, stay tuned...
Financial Indicators
EPS
No Data
Total revenue
No Data
Company
Biohaven Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development, and commercialization of treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its clinical and preclinical programs include Kv7 ion channel modulation for epilepsy and mood disorders; extracellular protein degradation for immunological diseases; Transient Receptor Potential Melastatin 3 (TRPM3) antagonism for migraine and neuropathic pain; Tyrosine Kinase 2/Janus Kinase 1 (TYK2/JAK1) inhibition for neuroinflammatory disorders; glutamate modulation for obsessive-compulsive disorder (OCD) and spinocerebellar ataxia (SCA); myostatin inhibition for neuromuscular and metabolic diseases, including spinal muscular atrophy (SMA) and obesity; and antibody recruiting, bispecific molecules and antibody drug conjugates (ADCs) for cancer. The Troriluzole is a new chemical entity (NCE) and tripeptide prodrug of the active metabolite, riluzole.
Ticker SymbolBHVN
CompanyBiohaven Ltd
CEODr. Vlad Coric, M.D.
Websitehttps://www.biohaven.com/
Related Instruments
-0.52%
+4.85%
-2.53%
-1.09%
-0.53%
-8.14%
-1.53%
+2.60%
-0.17%
+0.12%
-0.74%
+0.22%
-2.25%
-1.13%
-0.98%
-1.17%
-1.65%
+1.26%
0.00%
-3.12%
